Abivax's CEO, Marc de Garidel, announced plans to raise capital after the results of a second late-stage trial for its lead drug, obefazimod, are expected in late June. This drug is considered a potential best-in-class treatment for ulcerative colitis and is also being evaluated for Crohn's disease, which could tap into a lucrative market for Irritable Bowel Syndrome.
The company has seen its stock soar nearly 1,700% in 2025, driven by takeover rumors and positive trial results. De Garidel emphasized that the company is not in a hurry to sell, as it anticipates better terms for partnerships post-trial results.
He indicated that Abivax would likely pursue a combination of equity financing and debt to raise several million euros, although it currently has sufficient cash reserves of 530 million euros ($613 million) to sustain operations until late 2027.
The upcoming trial results are viewed as a critical inflection point for both the company and potential investors, with the market closely monitoring developments